Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 15/20 | 0.51 |
| ▸ | PGR | P06401 | 15/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | SHBG | P04278 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3766911 | 0.88 | AR (0.51) | ARPGRNR3C2LMNASLC6A4 | |
| SCHEMBL16564596 | 0.86 | AR (0.49) | ARPGRNR3C2LMNASLC6A4 | |
| SCHEMBL11647082 | 0.82 | AR (0.61) | ARPGRNR3C2LMNASLC6A4 | |
| SCHEMBL12904866 | 0.81 | AR (0.51) | ARPGRNR3C2LMNASLC6A4 | |
| SCHEMBL13797484 | 0.81 | AR (0.51) | ARPGRNR3C2LMNASLC6A4 | |
| SCHEMBL13797572 | 0.81 | AR (0.51) | ARPGRNR3C2LMNASLC6A4 | |
| SCHEMBL13557258 | 0.79 | AR (0.51) | ARPGRNR3C2LMNASLC6A4 | |
| SCHEMBL924304 | 0.79 | AR (0.50) | ARPGRNR3C2LMNASLC6A4 | |
| SCHEMBL925989 | 0.79 | AR (0.50) | ARPGRNR3C2LMNASLC6A4 | |
| SCHEMBL4102313 | 0.79 | AR (0.54) | ARPGRNR3C2LMNASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038294-B1 | 18-METHYL-19-NOR-ANDROST-4-EN-17,17-SPIROETHER (18-METHYL-19-NOR-20- SPIROX-4-EN-3-ONE) AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | BAYER SCHERING PHARMA AG (DE) | 2010-12-08 | — | — | EP | disclosed |
| US-7846917-B2 | 18-Methyl-19-norandrost-4-ene 17, 17-spiro ether (18-methyl-19-nor-20-spirox-4-en-3-one), and pharmaceutical products comprising the same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-20080153787-A1 | 18-Methyl-19-norandrost-4-ene 17, 17-spiro ether (18-methyl-19-nor-20-spirox-4-en-3-one), and pharmaceutical products comprising the same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153787-A1 | 18-Methyl-19-norandrost-4-ene 17, 17-spiro ether (18-methyl-19-nor-20-spirox-4-en-3-one), and pharmaceutical products comprising the same | NR3C2, HSD17B7, MC2R | AR 31/4885PGR 87/4885NR3C2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.